Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Council Members who Treat Colon/Colorectal Cancer

Articles with lock require a subscription to GLG News | Request a free trial
August 21, 2008
Artificial red blood cells (RBC'S): preliminary but very promising.
Analysis of: Scientists Find Way to Create Red Blood Cells | online.wsj.com
Author: GLG Expert Contributor
Advanced Cell Technology in Worcester, Mass., the University of Illinois at Chicago and the Mayo Clinic in Rochester, Minn. scientists say they've found an efficient way to make red blood cells from human embryonic stem cells. Impreesive!
August 21, 2008
Cervical Cancer Vaccines: Hope or Hype?
Analysis of: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise | www.nytimes.com
Author: GLG Expert Contributor
Cervical cancer vaccines manufactured by Merck and Glaxo have been hyped, pushed and if the companies have their way, mandated by various states and organizations. (Who is benefiting? Patients or the politicians?) There are many unanswered questions but marketing and mandates press on!
August 20, 2008
Sunitinib vs Interferon: No contest at the onset
Analysis of: Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma | jco.ascopubs.org
Author: GLG Expert Contributor
When using a model (of whose desin?) Pfizer's Sunitinib (Sutent) was found to be cost effective by Pfizer people? Surprise!!!
August 19, 2008
Cole & Pfizer: Happy together in NSCLCA (non small cell lung cancer)
Analysis of: Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
"The investigator-assessed objective response rate (complete and partial response), including both confirmed and unconfirmed responses, was 38% in the PF-3512676 plus chemotherapy arm and 19% in the chemotherapy-alone arm (P = .043)." In other words. IT MAY WORK!
Donald FlemingAugust 14, 2008
UK the model for US healthcare?
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for...
August 13, 2008
"Health-care costs are expected to rise more than 10% ".... and we can continue this for how long??
Analysis of: Insurers Expect Health-Care Costs To Rise More Than 10% Next Year | online.wsj.com
Author: GLG Expert Contributor
10% increase in medical spending when the overall cost of living is 1/2 of medical costs and we are happy??
August 11, 2008
Fair or Unfair Decision: the cost of the drugs for kidney cancer is more than the economy can bear.
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: GLG Expert Contributor
Pfizer’s Sutent, Wyeth’s Torisel, Bayer’s Nexavar and Avastin, sold by Roche and Genentech have been deemed too expensive to be paid for by UK agencies
August 7, 2008
Salmonella; Cancer cells?? Let's not get carried away
Analysis of: Salmonella Is Tested To Fight Cancer Cells | online.wsj.com
Author: GLG Expert Contributor
Salmonella targeting cancer cells? In humans???
August 6, 2008
Boy will this p.... off Urologists as well as AARP!
Analysis of: Panel Urges End to Prostate Screening at Age 75 | www.nytimes.com
Author: GLG Expert Contributor
Since treatment may be worse than the disease it is being recommended that routine prostate cancer screening be stopped after the age of 75.
August 1, 2008
More of the Same Crackdown on Amgen's Epo Agents
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
The FDA used new power to order Amgen to change its product label for its Epo Stimulating Agents (ESAs).  The new label will reflect what Medicare reimbursement guidelines have recently oulined.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 660

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163